SpiceJet has announced its financial results for the quarter and nine months ended December 31, 2024.

On February 27, 2025, SpiceJet share price opened at ₹48.06, up from its previous close of ₹47.975. At 9:52 AM, the share price of SpiceJet was trading at ₹45.60, down by 4.94% on the BSE.

Q3 FY 2025 Financial Highlights

The airline reported a net profit of ₹26 crore in Q3FY25, a recovery from a loss of ₹300 crore in the same quarter last year. Its total revenue surged by 35% to ₹1,651 crore, driven by strong passenger demand, improved yields, and enhanced operational efficiency.

The Passenger Load Factor (PLF) stood at 87%, reflecting high occupancy rates. Additionally, the company achieved a positive net worth of ₹70 crore.

9M Ended December 31, 2024 Financial Highlights

For the nine-month period ending December 2024, SpiceJet reduced its losses to ₹267 crore from ₹528 crore in the previous year. EBITDA for the period stood at ₹401 crore (₹524 crore ex-Forex) compared to ₹385 crore (₹466 crore ex-Forex) in the previous year. Total revenue for the period reached ₹3,838 crore, demonstrating steady growth in operations.

Other Significant Developments

During the year, the airline successfully settled multiple outstanding disputes with aircraft and engine lessors. These settlements, originally amounting to ₹1,700 crore, were resolved at ₹1,233 crore, resulting in a financial benefit of ₹467 crore. This has contributed to improving the company’s overall financial health.

SpiceJet also raised ₹3,000 crore through a Qualified Institutional Placement (QIP), which saw participation from leading global investors. The funds have significantly strengthened its financial position, enabling the resolution of legacy liabilities, fleet expansion, and accelerated operational growth.

Management Commentary

Commenting on the performance, the Chairman and Managing Director of SpiceJet, Ajay Singh, said, “This quarter’s performance is a testament to SpiceJet’s resilience and our relentless focus on financial and operational recovery. For the first time in a decade, the company has turned net worth positive – an important milestone that underscores the success of our turnaround strategy. The past is behind us, and we are now firmly focused on building a stronger, more resilient future for SpiceJet.”

He further added, “The overwhelming response to our QIP and the trust of global investors, combined with operational resilience and financial discipline, has set the stage for sustained growth. We have significantly strengthened our balance sheet, resolved key disputes, and are continuously expanding our fleet. We are in discussions with OEMs for advanced deliveries of aircraft and are actively exploring both organic and inorganic growth opportunities.”

Conclusion

SpiceJet’s Q3FY25 performance, debt settlements, and successful QIP fundraising highlight its financial recovery and growth momentum.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Jupiter Wagons Limited (JWL) informed the exchanges that Jupiter Tatravagonka Railwheel Factory Pvt. Ltd, the specialised wheelset manufacturing division of the company, has secured a prestigious ₹255 crore contract from Braithwait & Co. The contract involves supplying 9,140 wheelsets of 840 mm diameter for 25-ton axle load applications.

Strengthening Leadership in Railway Infrastructure

This order reinforces Jupiter’s position as a leading domestic manufacturer of high-performance railway wheelsets. With this latest contract, the company’s total order book now stands at ₹560 crore, reflecting its growing influence in India’s railway infrastructure sector.

Strategic Growth and Expansion Plans

As part of its long-term strategy, Jupiter aims to achieve ₹600 crore in revenue from its wheel business in FY26, nearly doubling its current contribution. This growth will be driven by enhanced production capacity, steady order inflows, and strengthened domestic manufacturing capabilities.

To support this vision, Jupiter is significantly expanding its manufacturing facilities. The company is setting up a state-of-the-art production facility in Odisha, which will increase its annual capacity from 20,000 forged wheels and axles to 1,00,000 forged wheelsets. This ambitious expansion is backed by a ₹2,500 crore investment, aligning with India’s goal of bolstering domestic manufacturing and reducing dependence on imports.

The Odisha facility is progressing on schedule, with the Commercial Operation Date (COD) for axle production expected by December 2026. The complete wheel and axle production unit is slated for completion by December 2027.

Diversification into Electric Mobility

Beyond railway manufacturing, Jupiter Electric Mobility Pvt. Ltd (JEM), JWL’s commercial EV arm, is preparing for the commercial launch of the JEM TEZ on March 3, 2025, in Indore. This marks a key step in Jupiter’s strategy to expand into sustainable mobility solutions.

Management Commentary

Commenting on the development, the Managing Director of Jupiter Wagons Limited, Mr Vivek Lohia, said, “This order from Braithwait & Co. underscores the trust in Jupiter Tatravagonka Railwheel Factory’s manufacturing excellence and our ability to meet the evolving demands of India’s railway sector. With the rapid expansion of freight and passenger rail networks, there is a critical need for reliable, high-performance wheelsets produced domestically at scale.”

He further added, “Our Odisha facility will be a game-changer in this space, ensuring India’s self-sufficiency in wheelset manufacturing while also positioning us as a global supplier. This milestone aligns with our commitment to strengthening the railway supply chain, reducing import dependency, and driving innovation in railway mobility solutions.”

Conclusion

Jupiter remains dedicated to innovation, strengthening India’s railway infrastructure, and driving the nation’s transportation growth through continued investments in advanced manufacturing and mobility solutions.

On February 27, 2025, JWL share price opened at ₹311.60, up from its previous close of ₹307.80. At 9:46 AM, the share price of JWL was trading at ₹301.80, down by 1.95% on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bonus shares are additional shares given to existing shareholders by a company without any extra cost, based on the number of shares they already own. These shares are issued from the company’s retained earnings or free reserves and serve as a reward to shareholders while increasing the company’s equity base.

For example, a company announces a 1:2 bonus issue. This means that for every two shares a shareholder owns, they will receive one additional share for free. If an investor holds 200 shares of the company before the bonus issue, they will receive 100 extra shares. After the bonus issue, their total holding will increase to 300 shares.

In this article, find out the stocks that are offering bonus shares in March 2025.

List of Bonus Issues in March 2025

Overview of the Company Issuing Bonus Shares in March 2025

1. Anand Rathi Wealth Ltd

Anand Rathi Wealth Ltd, incorporated on March 22, 1995, is an AMFI-registered mutual fund distributor and a leading non-bank wealth solutions firm in India. It ranks among the top three non-bank mutual fund distributors in the country. The company provides a diverse range of services, including wealth solutions, financial product distribution, and technology-driven solutions for its clients.

Anand Rathi Wealth announced a 1:1 bonus issue on January 13, 2025, with the ex-date on March 5, 2025.

2. Vantage Knowledge Academy Ltd

Vantage Knowledge Academy Ltd is involved in the business of Education and Publication. The company announced a 2:1 bonus issue, with the ex-date on March 5, 2025.

3. Pradhin Ltd

Pradhin Limited is involved in the business of producing, marketing and trading in all kinds of dairy products. The company announced a 2:1 bonus issue, with the ex-date on March 7, 2025.

4. SBC Exports Ltd

SBC Exports Ltd is engaged in the trading and manufacturing of garments, manpower supply and services and tour operator services.

The company announced a 1:2 bonus issue, with the ex-date on March 10, 2025.

5. Padam Cotton Yarns Ltd

Padam Cotton Yarns is involved in the manufacturing of cotton yarn and consulting. The company announced a 2:3 bonus issue, with the ex-date on March 18, 2025.

Conclusion 

Bonus shares are a strategic way for companies to reward shareholders while enhancing liquidity and investor confidence. Although they do not provide immediate monetary gains, they increase shareholding without additional investment. Investors should assess a company’s financial health before relying on bonus issues as a growth indicator. Apart from the above-mentioned, there can be other companies issuing bonus shares in March 2025. Stay tuned for further updates.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

International Gemmological Institute (India) Limited’s (IGIL) Board of Directors has declared and approved an interim dividend of ₹2.44 per equity share of ₹2 each.

On February 25, 2025, International Gemmological share price (NSE: IGIL) opened at ₹414.90 and closed at ₹407.00, down by 1.92%. The stock price touched its day’s low at ₹403.95.

International Gemmological Interim Dividend Record Date

The company has announced that the Board of Directors, in their meeting held on Saturday, February 22, 2025, approved the payment of an interim dividend of ₹2.44 (Two Rupees and Forty-Four Paise) per equity share of ₹2 each (122%) for the financial year 2024 (January 1, 2024, to December 31, 2024). The company has set Friday, February 28, 2025, as the record date to determine the eligibility of shareholders entitled to receive the interim dividend.

About International Gemmological Institute (India) Limited

International Gemmological Institute Ltd is the world’s largest independent provider of certification and accreditation services for diamonds, gemstones, and jewellery. The company provides certification and accreditation for natural diamonds, lab-grown diamonds, studded jewellery, and coloured stones, along with educational programs. Originally established in Belgium, it has expanded into a global network with 31 branches featuring IGI labs across 10 countries and 18 gemology schools across 6 countries.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

India is the world’s second-largest cement producer, contributing over 8% of global installed capacity. With significant growth potential in infrastructure and construction, the cement sector is poised to benefit substantially. In this article, check the best cement stocks in India for March 2025, based on the 5-year CAGR and other parameters like debt to equity ratio and net profit margin.

Best Cement Stocks in March 2025 – Based on 5yr CAGR

Note: The best cement stocks in India for March 2025 listed here are as of February 25, 2025. The stocks are picked from the Nifty 500 universe, with positive 1-year returns and are sorted based on the 5-yr CAGR.

Overview of the Best Cement Stocks in March 2025

1. India Cements Ltd

India Cements Ltd is amongst the leading cement manufacturing companies. The company’s consolidated net sales for Q3 FY25 stood at ₹940.81 crore, compared to ₹1,144.46 crore in the same period of the previous year. However, Profit After Tax (PAT) increased to ₹196.22 crores, up from ₹0.67 crores in Q3 FY24.

Key metrics:

• ROCE: -0.25%
• ROE: -3.98%

2. Grasim Industries Ltd

Grasim Industries Limited is the flagship company of the Aditya Birla Group. On a standalone basis, GIL’s core businesses have Viscose Staple Fibre (VSF), caustic soda, speciality chemicals, and rayon-grade wood pulp (RGWP), with manufacturing facilities at various locations. Additionally, the company is involved in other sectors such as fertilisers, textiles, and more.

In Q3 FY25, the company registered a revenue of ₹34,793 crore, reflecting a 9% YoY growth compared to ₹31,965 crore in Q3 FY24. The PAT declined to ₹899 crore, a 41% decrease from ₹1,514 crore in Q3 FY24.

Key metrics:

• ROCE: 7.19%
• ROE: 4.30%

3. J K Cement Ltd

J K Cement Ltd is into the manufacturing and selling of cement and cement-related products. The company has over 4 decades of experience in cement manufacturing. In Q3 FY25, the company reported a 14% quarter-on-quarter (QoQ) growth in revenue from operations, reaching ₹2,930 crore, compared to ₹2,560 crore in Q2 FY25. However, revenue remained almost flat on a year-on-year (YoY) basis, as it was ₹2,935 crore in Q3 FY24.

The company’s profit after tax (PAT) saw a 40% QoQ increase, rising to ₹190 crore in Q3 FY25, up from ₹136 crore in Q2 FY25. However, compared to the same period last year, PAT declined by 33% from ₹284 crore in Q3 FY24.

Key metrics:

• ROCE: 14.27%
• ROE: 15.88%

4. UltraTech Cement Ltd

UltraTech Cement is engaged in the manufacturing and sale of cement and cement-related products mainly across the globe. The company’s consolidated net sales for Q3 FY25 were ₹16,971 crore, compared to ₹16,487 crore in the same period of the previous year. Profit after tax decreased to ₹1,470 crores during Q3 FY25, compared to ₹1,777 crores in the previous year.

Key metrics:

• ROCE: 14.06%
• ROE: 12.22%

5. Shree Cement Ltd

Shree Cement is involved in the manufacturing and selling of cement and cement-related products. For the quarter ended December 31, 2024, the company reported a net revenue from operations of ₹4,235 crore, reflecting a 13% decline year-on-year (YoY) from ₹4,873 crore but a 14% increase quarter-on-quarter (QoQ) from ₹3,727 crore. The profit after tax stood at ₹229 crore, marking a 69% drop YoY from ₹734 crore. However, on a QoQ basis, the profit surged by 146% from ₹93 crore.

Key metrics:

• ROCE: 14.76%
• ROE: 12.15%

Best Cement Stocks in March 2025 – Based on Debt to Equity Ratio

Note: The best cement stocks in India for March 2025 listed here are as of February 25, 2025. The stocks are picked from the Nifty 500 universe and are sorted based on the low debt-to-equity ratio.

Best Cement Stocks in March 2025 – Based on Net Profit Margin

Note: The best cement stocks in India for March 2025 listed here are as of February 25, 2025. The stocks are picked from the Nifty 500 universe and are sorted based on the net profit margin.

Cement Sector Growth in India

India ranks as the world’s second-largest cement producer, contributing over 8% to the global installed capacity. With significant growth potential in the infrastructure and construction sectors, the cement industry is poised to benefit substantially. Additionally, rising rural housing demand has been driving steady cement consumption.

In 2023, India’s cement market size stood at 3.96 billion tonnes and is projected to reach 5.99 billion tonnes by 2032, growing at a CAGR of 4.7% from 2024 to 2032. Cement consumption is expected to rise to 450.78 million tonnes by the end of FY27.

Who Can Invest in Cement Stocks?

Cement sector stocks can offer a viable investment opportunity for long-term investors seeking to benefit from India’s expanding infrastructure and real estate sectors. With consistent demand, relatively low volatility, and dividend potential, these stocks can be appealing to conservative investors. However, investors should be mindful of cyclical demand fluctuations influenced by macroeconomic factors like interest rates and government policies.

Conclusion

The cement sector in India can provide growth prospects driven by infrastructure development and urbanisation. However, investors must carefully analyse each company’s financials, market positioning, and risks before making an investment decision.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On February 25, 2025, the BSE Sensex was up by 0.20% closing at 74,602.12, while the Nifty50 was down by 0.03% at 22,547.55. Among sectors, the Nifty Metal and Nifty Realty declined by over 1.3% each.

Top Gainers of the Day

• Bharti Airtel

Bharti Airtel share price gained 2.32% after opening at ₹1,597.00. The stock touched the day’s high at ₹1,649.15. Bharti Airtel and Ericsson have expanded their partnership with a new collaboration to deploy Ericsson’s secure and high-performance 5G Core network.

• Mahindra & Mahindra (M&M)

M&M share price rose by 2.13%. The share price opened at ₹2,740.00 and touched its day’s high at ₹2,803.95.

• Bajaj Finance

Bajaj Finance share price surged 1.40% after opening at ₹8,354.95. It hit a day’s high of ₹8,526.65.

• Nestle India

Nestle India share price surged 1.36% after opening at ₹2,222.45. It hit a day’s high of ₹2,256.40.

• Titan Company

Titan share price surged 0.87% after opening at ₹3,140.00. It hit a day’s high of ₹3,211.50.

Top Losers of the Day

• Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories share price dropped 3.10%. The stock opened at ₹1,167.15 and touched its day’s low at ₹1,122.50.

• Hindalco Industries

Hindalco share price slipped 3.01%. The share price opened at ₹636.00 and touched its day’s low at ₹617.10.

• Trent

Trent share price fell 2.41%. The share price opened at ₹5,090.00 and touched its day’s low at ₹4,936.30.

• Hero MotoCorp

Hero MotoCorp share price slipped 1.72%. The share price opened at ₹3,877.00 and touched its day’s low at ₹3,817.10.

• Sun Pharmaceutical Industries

Sun Pharma share price slipped 1.70%. The share price opened at ₹1,639.50 and touched its day’s low at ₹1,606.25.

Conclusion

Today’s top gainers and losers highlight the dynamic nature of the stock market, driven by factors such as corporate earnings, economic data, and global trends. Investors should stay informed and assess market movements carefully before making investment decisions.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Zaggle Prepaid Ocean Services Limited has entered into a strategic agreement with Honasa Consumer Limited, the parent company of Mamaearth. Under this contract, Zaggle will provide its Zoyer Platform to Honasa Consumer, facilitating improved financial and expense management solutions.

Nature of the Contract

The agreement is classified as a Customer Service Agreement and is purely domestic in nature. The collaboration is expected to enhance operational efficiencies for Honasa Consumer, leveraging Zaggle’s expertise in prepaid solutions and financial technology.

Contract Duration and Execution

The agreement spans 36 months, during which Zaggle will deliver its services as per the agreed terms. This long-term partnership is set to benefit both companies, reinforcing Zaggle’s role in digital payment solutions.

Conclusion

This partnership marks another milestone for Zaggle Prepaid Ocean Services as it continues to expand its offerings in the Indian market, catering to businesses with innovative financial solutions.

On February 25, 2025, Zaggle share price opened at ₹353.90, almost the same as its previous close of ₹353.05. At 11:48 AM, the share price of Zaggle Prepaid Ocean Services was trading at ₹360.35, up by 2.07% on the NSE.

On the other hand, Honasa share price opened at ₹220.00, slightly lower than its previous close of ₹223.32. At 11:50 AM, the share price of Honasa was trading at ₹224.11, up by 0.35% on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the launch of YESINTEK™ (ustekinumab-kfce) in the United States.

A Cost-Effective Biosimilar for Autoimmune Diseases

This marks a significant milestone for BBL as one of the first biosimilar alternatives to Stelara® (ustekinumab) in the U.S. market. YESINTEK is approved for treating Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, providing a more cost-effective treatment option for patients with chronic autoimmune diseases.

It will be available in the same formulations as Stelara, including pre-filled syringes (PFS) and vials in multiple dosage strengths.

YESINTEK will have commercial payor coverage at launch and a comprehensive patient assistance program, offering copay support and benefits verification. Eligible patients may pay as little as $0 under the copay program, making the treatment more accessible.

The drug is a monoclonal antibody that inhibits IL-12 and IL-23 signalling, both of which are linked to immune-mediated diseases. Clinical studies confirmed that YESINTEK has comparable safety, efficacy, pharmacokinetics, and immunogenicity to Stelara.

FDA Approval and Market Expansion in the U.S.

With FDA approval granted in December 2024, Biocon Biologics aims to expand patient access to advanced biologic therapies while driving affordability in the U.S. healthcare market.

The CEO and Managing Director of Biocon Biologics Ltd, Shreehas Tambe, said, “The launch of YESINTEK marks a significant step in our commitment to improving the lives of patients with inflammatory conditions and expanding access to high-quality biosimilars. It also represents our first product launch in the United States since becoming a fully integrated global biosimilars organisation. We are excited to be among the first companies to introduce a high-quality, affordable biosimilar Ustekinumab to this patient population.”

Laura Wingate, Chief Education, Support & Advocacy Officer of the Crohn’s & Colitis Foundation, stated, “The burden of Crohn’s disease and ulcerative colitis on patients’ daily lives is substantial. This is a meaningful advancement for eligible chronic disease patients, who now have more treatment options available.”

Conclusion

YESINTEK’s launch in the U.S. enhances access to affordable treatment for autoimmune diseases. With support programs, it offers a viable Stelara® alternative.

On February 25, 2025, Biocon share price opened at ₹324.05, touching the day’s high at ₹329.00, as of 10:56 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Star Health and Allied Insurance Company Limited (Star Health Insurance), India’s largest retail health insurance provider, has expanded its Home Health Care (HHC) initiative to 100 locations across the country.

Launched in July 2023, the program now serves over 85% of the company’s customer base, offering cashless medical care at home within three hours without out-of-pocket expenses. This expansion enhances the accessibility, affordability, and availability of healthcare, particularly in underserved regions.

Medical Care at Home

The HHC program is designed to provide prompt medical attention for patients recovering from infectious diseases. Under this initiative, a partner doctor visits the patient’s home to assess their condition, diagnose symptoms, and administer necessary treatment if hospitalisation is not required. The program includes regular in-person follow-ups to monitor recovery. In cases where symptoms are severe, the doctor may recommend hospitalization, though less than 1% of patients have required such escalation.

Widespread Adoption and Partnerships

The initiative has gained significant traction in cities like Mumbai, Delhi, and Pune, where patients have primarily sought treatment for conditions such as viral fever, dengue, enteric fever, acute gastroenteritis, and respiratory infections. More than 15,000 patients have benefitted from the program, which operates through partnerships with leading healthcare providers, including Care24, Portea, Argala, Athulya, and Apollo.

Commenting on this, the MD and CEO of Star Health Insurance, Anand Roy, said, “At Star Health, we believe that health insurance goes beyond providing financial coverage. It is a bridge to accessible and affordable healthcare for every individual. Our vision is to remove barriers such as high hospitalization costs, logistical challenges and the stress associated with seeking care. By bringing quality medical care closer to customers we aim to ensure their comfort and peace of mind. This initiative is tangible proof of our focus on transforming health insurance delivery by ensuring that it is accessible, affordable, and designed around the evolving needs of our customers.”

Conclusion

This expansion enhances the accessibility, affordability, and availability of healthcare, particularly in underserved regions. On February 25, 2025, Star Health share price opened at ₹378.25, touching the day’s low at ₹367.50, as of 11:09 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.